This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Burden of Disease
Burden of Disease
Risk Factors
Secondary Infections
Mechanism of Action
Prevention of Pneumococcal Disease
Need for Pneumococcal Vaccination
Cost-effectiveness of PCV13
Legacy of Prevenar
Safety
Conclusion
Dosing
Prevenar 13® Clinical Experience
Efficacy of Prevenar 13®
Effectiveness of Prevenar 13®
Indian Clinical Trials
Recommendations for Use
PCV13 in Pulmonology
PCV13 in Nephrology
PCV13 in Oncology
PCV13 in Rheumatology
PCV13 in Diabetes
PCV13 in HIV Infection
PCV13 in Cardiology
Resources
What Are the National and Global Recommendations for the Use of Pneumococcal Vaccines in Chronic Lung Disease?
Pneumococcal vaccination is recommended for use in patients with chronic lung diseases, including COPD,by various global bodies and respiratory societies, like GOLD (2020), Swiss Respiratory Society (2013), British Columbia Medical Association (2011), CDC’s ACIP (2019), the Portuguese Respiratory Society (2014), the Spanish Society of Pneumology and Thoracic Surgery, the Philippine Society for Microbiology and Infectious Diseases and Royal College of Physicians of Thailand.1-8
CDC’s ACIP (2019) recommends the use of PCV13 in persons aged ≥65 years with chronic lung diseases based on shared clinical decision-making. One dose of PPSV23 is recommended for persons aged <65 years with chronic lung disease. For persons aged ≥65 years, 1 dose of PPSV23 is recommended; if PCV13 has been administered, then PPSV23 should be given ≥1 year after PCV13 and ≥5 years after any PPSV23 at age <65 years. The Portuguese Respiratory Society (2014) recommended the sequential administration of PCV13 and PPSV23 in adults aged ≥50 years with chronic respiratory diseases, including chronic asthma under inhaled corticosteroid. The Spanish Society of Pneumology and Thoracic Surgery (2013) in a joint consensus document recommended the use of PCV13 in chronic respiratory diseases (including COPD, asthma and interstitial lung disease). The Philippine Society for Microbiology and Infectious Diseases and Royal College of Physicians of Thailand also recommended the use of PCV13 in patients with chronic lung diseases.7,8
The API (2014) recommended the use of pneumococcal vaccines in adults aged ≥50 years with predisposing conditions, including chronic lung disease. Other national guidelines that recommend the use of pneumococcal vaccines in chronic lung diseases include those from the IAOH (2020), IMA, etc. The IAOH, API and IMA recommend the use of PCV13 and PPSV23 in high-risk adults aged between 50 and 64 years. The high-risk group of adults includes patients with COPD. In these cases, PCV13 should be administered first followed by PPSV23 after 8 weeks. Thereafter, PPSV23 can be repeated after 5 years.9-11
ACIP, Advisory Committee on Immunization practices; API, Association of Physicians of India; CDC, Centers for Disease Control and Prevention; COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; IMA, Indian Medical Association; IAOH, Indian Association of Occupational Health; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal plain polysaccharide vaccine.
References:
Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-PRV-IND-0268 July 2022
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Efficacy proven by the CAPiTA study
Learn more
The ACIP recommends routine use of PCV13 among adults
Learn more
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.